Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANNX NASDAQ:BEAM NYSE:OGN NASDAQ:ORKA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANNXAnnexon$5.36-0.3%$5.63$1.85▼$7.18$878.67M1.222.52 million shs1.25 million shsBEAMBeam Therapeutics$33.50+2.1%$28.02$15.35▼$36.44$3.45B2.262.02 million shs719,658 shsOGNOrganon & Co.$13.38+0.2%$10.00$5.69▼$13.48$3.51B1.577.57 million shs986,340 shsORKAOruka Therapeutics$57.89-0.2%$59.34$10.64▼$91.00$3.49B-0.21.06 million shs679,969 shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANNXAnnexon-0.37%-1.29%-10.50%-4.11%+164.53%BEAMBeam Therapeutics+2.85%+18.54%+7.33%+15.25%+94.31%OGNOrganon & Co.-0.16%-0.52%+0.15%+82.82%+45.80%ORKAOruka Therapeutics-0.02%-1.21%-21.64%+68.50%+405.49%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANNXAnnexon$5.36-0.3%$5.63$1.85▼$7.18$878.67M1.222.52 million shs1.25 million shsBEAMBeam Therapeutics$33.50+2.1%$28.02$15.35▼$36.44$3.45B2.262.02 million shs719,658 shsOGNOrganon & Co.$13.38+0.2%$10.00$5.69▼$13.48$3.51B1.577.57 million shs986,340 shsORKAOruka Therapeutics$57.89-0.2%$59.34$10.64▼$91.00$3.49B-0.21.06 million shs679,969 shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANNXAnnexon-0.37%-1.29%-10.50%-4.11%+164.53%BEAMBeam Therapeutics+2.85%+18.54%+7.33%+15.25%+94.31%OGNOrganon & Co.-0.16%-0.52%+0.15%+82.82%+45.80%ORKAOruka Therapeutics-0.02%-1.21%-21.64%+68.50%+405.49%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANNXAnnexon 2.43Hold$16.00193.85% UpsideBEAMBeam Therapeutics 2.71Moderate Buy$46.8340.07% UpsideOGNOrganon & Co. 1.71Reduce$11.40-14.77% DownsideORKAOruka Therapeutics 2.82Moderate Buy$120.80107.29% UpsideCurrent Analyst Ratings BreakdownLatest ANNX, OGN, ORKA, and BEAM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/21/2026BEAMBeam Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$80.005/18/2026ORKAOruka Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$120.005/15/2026OGNOrganon & Co. Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)5/14/2026ORKAOruka Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$151.005/13/2026BEAMBeam Therapeutics Tudor PickeringSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$39.005/13/2026BEAMBeam Therapeutics Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$40.00 ➝ $39.005/12/2026ANNXAnnexon The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$7.005/12/2026ANNXAnnexon The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$7.004/30/2026ORKAOruka Therapeutics Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$120.004/29/2026ORKAOruka Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$75.00 ➝ $120.004/29/2026OGNOrganon & Co. BNP Paribas ExaneSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform ➝ Neutral$12.00 ➝ $14.00(Data available from 5/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANNXAnnexonN/AN/AN/AN/A$1.25 per shareN/ABEAMBeam Therapeutics$139.74M24.62N/AN/A$11.32 per share2.95OGNOrganon & Co.$6.22B0.57$5.79 per share2.31$3.44 per share3.89ORKAOruka TherapeuticsN/AN/AN/AN/A$8.02 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANNXAnnexon-$206.69M-$1.22N/AN/AN/AN/A-101.19%-75.99%8/13/2026 (Estimated)BEAMBeam Therapeutics-$79.99M-$0.68N/AN/AN/A-39.66%-29.00%-22.61%8/4/2026 (Estimated)OGNOrganon & Co.$187M$0.9314.383.891.243.99%99.95%6.22%8/4/2026 (Estimated)ORKAOruka Therapeutics-$105.43M-$1.94N/AN/AN/AN/A-26.16%-25.00%8/10/2026 (Estimated)Latest ANNX, OGN, ORKA, and BEAM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026ORKAOruka Therapeutics-$0.52-$0.48+$0.04-$0.48N/AN/A5/7/2026Q1 2026ANNXAnnexon-$0.30-$0.23+$0.07-$0.23$5.50 millionN/A5/7/2026Q1 2026BEAMBeam Therapeutics-$1.0278-$0.91+$0.1178-$0.91$10.98 million$31.74 million4/30/2026Q1 2026OGNOrganon & Co.$0.83$0.71-$0.12$0.55$1.49 billion$1.46 billion3/30/2026Q4 2025ANNXAnnexon-$0.32-$0.28+$0.04-$0.28$3.25 millionN/A3/12/2026Q4 2025ORKAOruka Therapeutics-$0.61-$0.45+$0.16-$0.45N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthANNXAnnexonN/AN/AN/AN/AN/ABEAMBeam TherapeuticsN/AN/AN/AN/AN/AOGNOrganon & Co.$0.080.60%N/A8.60%N/AORKAOruka TherapeuticsN/AN/AN/AN/AN/ALatest ANNX, OGN, ORKA, and BEAM DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/30/2026OGNOrganon & Co.quarterly$0.020.6%5/11/20265/11/20266/11/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANNXAnnexonN/A6.356.35BEAMBeam Therapeutics0.0916.9916.99OGNOrganon & Co.9.471.971.42ORKAOruka TherapeuticsN/A23.7623.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANNXAnnexonN/ABEAMBeam Therapeutics99.68%OGNOrganon & Co.77.43%ORKAOruka Therapeutics56.44%Insider OwnershipCompanyInsider OwnershipANNXAnnexon11.87%BEAMBeam Therapeutics3.80%OGNOrganon & Co.1.62%ORKAOruka Therapeutics23.49%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANNXAnnexon60163.84 million144.40 millionOptionableBEAMBeam Therapeutics510102.88 million98.97 millionOptionableOGNOrganon & Co.10,000262.60 million258.35 millionNot OptionableORKAOruka TherapeuticsN/A60.31 million46.15 millionN/AANNX, OGN, ORKA, and BEAM HeadlinesRecent News About These CompaniesOruka Therapeutics to Present at the 2026 Jefferies Global Healthcare ConferenceMay 28 at 8:00 AM | globenewswire.comCarl Dambkowski Sells 105,000 Shares of Oruka Therapeutics (NASDAQ:ORKA) StockMay 24, 2026 | americanbankingnews.comOruka Therapeutics (NASDAQ:ORKA) Director Carl Dambkowski Sells 105,000 SharesMay 23, 2026 | insidertrades.comQ2 EPS Forecast for Oruka Therapeutics Increased by AnalystMay 20, 2026 | marketbeat.comOruka Therapeutics (NASDAQ:ORKA) SVP Arjun Agarwal Sells 10,290 SharesMay 19, 2026 | americanbankingnews.comOruka Therapeutics (NASDAQ:ORKA) SVP Sells $607,830.30 in StockMay 19, 2026 | insidertrades.comInsider Selling: Oruka Therapeutics (NASDAQ:ORKA) Insider Sells $432,950.00 in StockMay 18, 2026 | americanbankingnews.comOruka Therapeutics (ORKA) Valuation Check After Psoriasis Trial Progress Partnerships And Fresh FundingMay 16, 2026 | finance.yahoo.comOruka Therapeutics (NASDAQ:ORKA) Insider Sells $432,950.00 in StockMay 16, 2026 | insidertrades.comOruka Therapeutics (ORKA) price target increased by 50.51% to 138.41May 14, 2026 | msn.comOruka Therapeutics, Inc.: Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 14, 2026 | finanznachrichten.deWhy This Biotech Fund Increased Its Oruka Therapeutics Stake Amid a Staggering 500% RallyMay 14, 2026 | fool.comOruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 13, 2026 | globenewswire.comWhy Oruka Therapeutics (ORKA) Is Down 6.3% After $700 Million Follow-On Amid Psoriasis BreakthroughMay 11, 2026 | finance.yahoo.comOruka Therapeutics, Inc. (NASDAQ:ORKA) Given Average Recommendation of "Moderate Buy" by BrokeragesMay 11, 2026 | marketbeat.comLeerink Partners Lifts PT on Oruka Therapeutics, Inc. (ORKA)May 10, 2026 | insidermonkey.com5 Best Performing Healthcare Stocks So Far in 2026May 8, 2026 | insidermonkey.comOruka Therapeutics (ORKA) slides 8.2% as investors digest recent $700M equity raiseMay 7, 2026 | quiverquant.comQHalozyme and Oruka sign agreement for Hypercon technologyMay 7, 2026 | pharmaceutical-technology.comPHalozyme Therapeutics, Inc.: Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon TechnologyMay 6, 2026 | finanznachrichten.deHalozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ TechnologyMay 6, 2026 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 2026Apple Talks Just Changed Everything for IntelBy Sam Quirke | May 6, 20263 Energy Stocks to Buy and 2 to Avoid as AI Power Demand ExplodesBy Bridget Bennett | May 4, 2026SpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 2026Sony's $4 Billion Bet on Rock & Roll RoyaltiesBy Jeffrey Neal Johnson | May 12, 2026ANNX, OGN, ORKA, and BEAM Company DescriptionsAnnexon NASDAQ:ANNX$5.36 -0.02 (-0.28%) As of 03:21 PM Eastern This is a fair market value price provided by Massive. Learn more.Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.Beam Therapeutics NASDAQ:BEAM$33.50 +0.70 (+2.13%) As of 03:21 PM Eastern This is a fair market value price provided by Massive. Learn more.Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.Organon & Co. NYSE:OGN$13.38 +0.03 (+0.19%) As of 03:21 PM Eastern This is a fair market value price provided by Massive. Learn more.Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.Oruka Therapeutics NASDAQ:ORKA$57.89 -0.09 (-0.16%) As of 03:21 PM Eastern This is a fair market value price provided by Massive. Learn more.Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys Dollar Tree Keeps Winning After Family Dollar Divorce Salesforce Stock Finds Support as AI Momentum Builds Marvell’s Pullback May Be the Setup Bulls Were Waiting For Snowflake and the Snowballing Impact of its AI Flywheel China Deal Ignites Boeing's Financial Afterburners IREN Is Flipping the Switch from Bitcoin to AI Flight Path to Profits: American Airlines Bets on SpaceX Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
